In a randomized, phase II trial led by researchers at MD Anderson Cancer Center, adding the PARP inhibitor veliparib to a standard chemotherapy agent improved overall response rates in patients with small cell lung cancer.
A study authored by scientists from the American Cancer Society, the Harvard T.H. Chan School of Public Health, the U.S. National Cancer Institute, and more than 20 other medical centers and organizations finds that higher circulating vitamin D concentrations are significantly associated with lower colorectal cancer risk.
Research from Roswell Park Comprehensive Cancer Center suggests a new treatment combination can extend survival for many patients with advanced colorectal cancer.
Exact Sciences, Mayo Clinic identify blood-based DNA biomarkers to diagnose hepatocellular carcinoma
Researchers at Exact Sciences Corp. and Mayo Clinic announced progress toward developing a panel of novel, blood-based, DNA biomarkers that could accurately detect hepatocellular carcinoma, the most common cancer that originates in the liver.
Bristol-Myers Squibb Co. announced updated results from the phase III CheckMate -238 trial evaluating Opdivo (nivolumab) versus Yervoy (ipilimumab) in patients with stage IIIB/C or stage IV melanoma who are at high risk of recurrence following complete surgical resection.
Bristol-Myers Squibb Co. announced patient-reported outcomes data from the phase III CheckMate -214 trial in intermediate- and poor-risk patients with advanced renal cell carcinoma treated with the immuno-oncology combination Opdivo (nivolumab) plus low-dose (1mg/kg) Yervoy (ipilimumab) vs. sunitinib over a two-year follow-up period.
Genentech said the phase III IMpower130 study met its co-primary endpoints of overall survival and progression-free survival.
The main findings of a new analysis of the landmark Framingham Heart Study by researchers at Vanderbilt University Medical Center published May 16 by the Journal of the National Cancer Institute shows that the risk of lung cancer drops substantially within five years of quitting.
Breast cancer survivors are not getting the recommended level of screening, post-surgery, according to a study in JNCCN – Journal of the National Comprehensive Cancer Network.
MimiVax LLC announced positive interim results from a multicenter phase II study of SurVaxM in patients with newly diagnosed glioblastoma.
